Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Gary S. StetzInterim CEO | Hepion PharmaceuticalsHEPA | Open-market buy | 04/21 | 04/27 | 1,250,000 sh | $0.04 | $50,000 | No record |
Hepion PharmaceuticalsHEPA | Open-market buy | 04/21 | 04/27 | 6,250,000 sh2 trades | $0.04avg. | $250,000 | No record | |
Michael J. PurcellDirector | Hepion PharmaceuticalsHEPA | Open-market buy | 04/21 | 04/27 | 1,250,000 sh | $0.04 | $50,000 | No record |
Sireesh AppajosyulaDirector | Hepion PharmaceuticalsHEPA | Open-market buy | 04/21 | 04/27 | 1,250,000 sh | $0.04 | $50,000 | No record |
Hepion PharmaceuticalsHEPA | Open-market buy | 23/11/24–23/11/27 | 23/11/28 | 5,000 sh2 trades | $3.07avg. | $15,350 | +111.1% | |
Hepion PharmaceuticalsHEPA | Open-market buy | 23/09/15–23/09/19 | 23/09/20 | 3,000 sh4 trades | $5.61avg. | $16,841.12 | +199.9% | |
Robert T. FosterCEO and Director | Hepion PharmaceuticalsHEPA | Open-market buy | 23/09/18 | 23/09/19 | 1,600 sh | $5.60 | $8,960 | +3.3% |
Robert T. FosterCEO,CSO and Director | Hepion PharmaceuticalsHEPA | Open-market buy | 23/09/15 | 23/09/18 | 1,600 sh | $5.40 | $8,640 | +3.4% |